PURMX Therapeutics
purmx.com
Actively hiring
Higher Education
Biotechnology
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
2
Keio Innovation Initiative, UTEC
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
2021
Founded
Backed byfrom the funds' portfolios and accelerator catalogs
Keio Innovation Initiative 
UTEC Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing advanced RNA treatments against genetic diseases.
Restoring Self Tolerance to the Immune System to Transform the Treatment of Autoimmune Diseases.
Forward thinking to reverse cell ageing. SENISCA targets the process of cellular ageing (senescence) via the development of RNA…
Prometech Software, Inc. was founded by experienced professionals and researchers at the University of Tokyo in 2004.
Endo Axiom — an enzyme-responsive oral platform for biologics. Lead programme: Type 1 diabetes. Next: autoimmune prevention and…
Lamina's Tech: A Game-Changer in Regenerative Medicine. Spin-off from INSERM - University of Strasbourg UMR1260 Regenerative Nanomedicine…
Overview
Promising and Ultimate RNA Medicine. Aiming innovative nucleic acid drugs that cure patients.
News
PURMX Therapeutics Co., Ltd. announced that it has received funding from Nippon Shokubai Co., Ltd.
Read more
Report
日本触媒、PURMX社と薬物送達DDS材料「Fol-Dab8」に関する技術連携を開始
天然型マイクロRNAとの組み合わせによる「Fol-Dab8」の創薬への適用可能性を検証株式会社日本触媒本社：大阪市中央区、代表取締役社長：野田 和宏は、自社保有のDDS1材料「Fol-Dab8葉酸結合型カチオン性ペプチド」の適応領域拡大に向け、株式会社PURMX Therapeutics本社：広島市南区、代表取締役社長 CEO：田原 栄俊、以下「PURMX社」との共同検証を開始しました
Read more
Report
PURMX Enters into Capital Alliance with Nippon Shokubai Co., Ltd. and Initiates Research to Validate the Potential of Fol-Dab8-microRNA Complexes
PURMX Therapeutics, Inc. (Headquartered in Hiroshima, Japan; President and CEO: Hidetoshi Tahara) is pleased to announce that it has initiated research to validate the potential of complexes comprising microRNA and Fol-Dab8, a drug delivery system (DDS) b
Read more
Report
株式会社日本触媒との資本提携の実施及びFol-Dab8・マイクロRNA複合体の有用性検証に関する研究の開始について
株式会社PURMX Therapeutics本社：広島市南区、代表取締役社長CEO：田原 栄俊、以下「PURMX」は、株式会社日本触媒本社：大阪市中央区、代表取締役社長：野田 和宏、以下「日本触媒」が提供するDDSDrug Delivery SystemであるFol-Dab8葉酸受容体αFOLR1を標的とし、選択的に核酸を送達するカチオン性ペプチドを基盤としたDDSとマイクロRNAの複合体の有用性を検証する研究を実施することとなりました 本研究の開始に合わせ、日本触媒はPURMXが実施した第三者割当増資を
Read more
Report
PURMX Enters into Capital Alliance with FRONTEO, Inc. and Launches PoC for AI-Driven microRNA Drug Discovery
PURMX Therapeutics, Inc.Headquartered in Hiroshima, Japan; President and CEO: Hidetoshi Taharais pleased to announce that we have commenced a proof of concept (PoC) to identify target molecules and elucidate the mechanism of action of our naturally occurr
Read more
Report
株式会社FRONTEOとの資本提携の実施及び難治性がん領域におけるマイクロRNA核酸医薬の標的分子候補探索・作用機序解明に向けたPoCの開始について
株式会社PURMX Therapeutics本社：広島市南区、代表取締役社長CEO：田原 栄俊、以下「PURMX」は、株式会社FRONTEO本社：東京都港区、代表取締役社長：守本 正宏、以下「FRONTEO」が提供するAI創薬支援サービス「Drug Discovery AI Factory (DDAIF)」を活用し、当社が開発する天然型マイクロRNAを有効成分とする核酸医薬品の標的分子探索・作用機序の明確化に向けたPoC実証実験を開始することとなりました 本PoCの開始に合わせ、FRONTEOはPURMX
Read more
Report
「MIRX002」悪性胸膜中皮腫を対象とした第I相試験において主要評価項目を達成
株式会社PURMX Therapeutics本社：広島市、代表取締役社長CEO：田原栄俊、以下「当社」は、当社が治験薬を提供してきた、天然型マイクロRNA補充療法による悪性胸膜中皮腫を対象とした医師主導治験である、単回投与試験SAD：Single Ascending Dose治験実施計画書番号：MIRX002-01および反復投与試験MAD：Multiple Ascending Dose治験実施計画書番号：MIRX002-02の両試験が終了し、それぞれの試験における主要評価項目である安全性および忍容性が達成
Read more
Report
"MIRX002" Achieves Primary Endpoint in Phase I Clinical Trial for Malignant Pleural Mesothelioma
PURMX Therapeutics, Inc. (Headquartered in Hiroshima, Japan; President and CEO: Hidetoshi Tahara; hereinafter "the Company") is pleased to announce the completion of both the Single Ascending Dose (SAD) study (Protocol No.: MIRX002-01) and the Multiple As
Read more
Report
PURMX Therapeutics Selected as an Awardee of the Japan Smart Healthy Aging QuickFire Challenge
PURMX Therapeutics, Inc. (Headquarters: Hiroshima-city, Hiroshima; President & CEO: Hidetoshi Tahara) is pleased to announce that it has been selected as an awardee of Johnson & Johnson's Japan Smart Healthy Aging QuickFire Challenge. This challenge invit
Read more
Report
PURMX Therapeutics Selected as an Awardee of the Japan Smart Healthy Aging QuickFire Challenge
PURMX Therapeutics, Inc. (Headquarters: Hiroshima-city, Hiroshima; President & CEO: Hidetoshi Tahara) is pleased to announce that it has...
Read more
Report
Show more news